- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03158532
Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin (Patens)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Transradial access (TRA) has been increasingly adopted for diagnostic and interventional cardiovascular procedures in many centers worldwide. This is largely driven by the evidence supporting an unequivocal reduction in access site-related complications associated with TRA compared with transfemoral access, as well as reduction in cost and increased patient comfort. The radial artery occlusion (RAO) is the main inconvenient and impose a limitation of future use of the radial artery as an access site for catheterization in the future. RAO is the most commun complication of transradial access, and its incidence continues to reach up to 12%.
Nitrates in intra-arterial have been widely studied in prevention of this spasm. Nitroglycerin binds to the surface of endothelial cells and undergoes two chemical reductions to form nitric oxide (NO). The nitric oxide then moves out of the endothelial cell and into an adjacent smooth muscle cell, where it promotes the formation of cyclic guanosine monophosphate (cGMP), which then promotes muscle relaxation. Current data show that nitroglycerin intra-arterial at the end of the procedure reduce the incidence of radial artery occlusion.
A big sheath to artery size ratio could reduce the incidence of RAO, so the main objective of this study is to evaluate whether administration of nitroglycerin at the start of a transradial procedure may preserve the patency of the radial artery; as well, confirm if nitroglycerin administration just before sheet removal helps to keep the radial artery patency.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Roberto L da Silva, MD
- Phone Number: +55 48 32719077
- Email: roberto.leo@ufsc.br
Study Locations
-
-
-
São Paulo, Brazil, 04012-909
- Not yet recruiting
- Instituto Dante Pazzanese de Cardiologia
-
Contact:
- Roberto L da Silva, MD
- Phone Number: +55 48 999099790
-
Principal Investigator:
- José R Costa Júnior, PhD
-
-
Distrito Federal
-
Brasília, Distrito Federal, Brazil, 70658-700
- Not yet recruiting
- Instituto de Cardiologia do Distrito Federal
-
Contact:
- Luciano M Santos, MD
- Phone Number: +55 61 3403-5400
-
Principal Investigator:
- Luciano M Santos, MD
-
-
SC
-
São Jose, SC, Brazil, 88000
- Recruiting
- Instituto de Cardiologia de Santa Catarina
-
Principal Investigator:
- Roberto L da Silva, MD
-
Contact:
- Roberto L da Silva, MD
- Phone Number: 55 48 32719077
- Email: roberto.leo@ufsc.br
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brazil, 88036-800
- Not yet recruiting
- Hospital Universitário Professor Polydoro Ernani de São Thiago
-
Contact:
- Thaís RW da Silva, PhD
- Phone Number: +55 48 37219100
-
Sub-Investigator:
- Thaís RW da Silva, MD
-
Principal Investigator:
- Roberto L da Silva, MD
-
-
São Paulo
-
Marília, São Paulo, Brazil, 17515-900
- Not yet recruiting
- Irmandade Santa Casa Misericórdia Marília
-
Contact:
- Pedro B Andrade, PhD
- Phone Number: +55 14 3402-5555
-
Principal Investigator:
- Pedro B Andrade, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Indication for cardiac catheterization;
- Suitable candidates for transradial approach;
- Use of 5 or 6 French sheath in the procedure;
- Signed informed consent.
Exclusion Criteria:
- Unable to tolerate nitrates or known allergy to nitrates;
- Use of any nitrate, by any route of administration, up to 1 hour before the procedure;
- ST-segment elevation acute myocardial infarction patients during the first 12 hours of sympton onset;
- Intubated patients (on mechanical ventilation);
- Complications before or during procedure (cardiac arrest, pulmonary edema, cardiogenic shock, stroke);
- Prior inclusion in this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo I/Placebo II
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
|
Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Other Names:
Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
Other Names:
|
EXPERIMENTAL: Nitroglycerin I/Placebo II
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
|
Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
Other Names:
500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Other Names:
|
ACTIVE_COMPARATOR: Placebo I /Nitroglycerin II
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
|
Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Other Names:
500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
Other Names:
|
EXPERIMENTAL: Nitroglycerin I /Nitroglycerin II
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
|
500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Other Names:
500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radial artery occlusion
Time Frame: 2 to 24 hours after procedure
|
Incidence of radial artery occlusion as confirmed by absence of antegrade flow in vascular doppler ultrasound
|
2 to 24 hours after procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Late radial artery occlusion
Time Frame: 30 days after procedure
|
Incidence of radial artery occlusion as confirmed by absence of antegrade flow in vascular doppler ultrasound
|
30 days after procedure
|
Pain assessment
Time Frame: up to 24 hours after procedure
|
Pain felt by the patient in the forearm, assessed using numeric pain rating scale
|
up to 24 hours after procedure
|
Spasm (operator evaluation)
Time Frame: Immediate
|
Catheter friction, as experienced by the operator (subjective measure)
|
Immediate
|
Procedure duration
Time Frame: Immediate
|
Total duration of the procedure, from puncture to haemostatic dressing.
|
Immediate
|
Radiation exposure
Time Frame: Immediate
|
Total radiation used in the procedure
|
Immediate
|
Collaborators and Investigators
Investigators
- Study Chair: Roberto L da Silva, MD, Instituto de Cardiologia de Santa Catarina
- Study Director: José R Costa Júnior, PhD, Instituto Dante Pazzanese de Cardiologia
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Nitroglycerin on Occlusion
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Injury of Radial Artery
-
Sheba Medical CenterWithdrawn
-
Oslo University HospitalHelse Sor-OstCompletedHemostasis | Injury of Radial Artery | Peripheral Artery OcclusionNorway
-
Hermina Heart Center KemayoranHermina Hospital GroupCompletedVasodilation | Radial Artery Injury at Wrist and Hand Level | Occlusion of ArteryIndonesia
-
Olivier F. BertrandRecruiting
-
TC Erciyes UniversityUnknownInjury of Radial Artery at Wrist and Hand Level | Injury; Ulnar Artery, Hand and WristTurkey
-
Kasr El Aini HospitalCompletedRadial Artery Injury PrevetionEgypt
-
National Cardiovascular Center Harapan Kita Hospital...Completed
-
National Heart Institute, MexicoUnknownComplication | Occlusion of Artery | Radial Artery InjuryMexico
-
NAUSICA InvestigatorsNPO International TRI NetworkCompletedPatency of the Radial ArteryJapan, India, Taiwan
-
Total Cardiovascular SolutionsCompletedRadial Artery Injury at Wrist and Hand LevelIndia
Clinical Trials on Placebo I
-
Hero Institute for Infant NutritionUniversidad de Murcia; University of Valencia; Universidad de GranadaCompletedConditions Influencing Health StatusSpain
-
National University Hospital, SingaporeCompleted
-
Mineralys Therapeutics Inc.CompletedHypertension, RenalUnited States
-
Bigespas LTDRecruitingAlzheimer Disease | Dementia of Alzheimer TypeRussian Federation
-
Bharat Biotech International LimitedIndian Council of Medical ResearchCompletedCOVID-19 | SARS-CoV-2 InfectionIndia
-
University of CopenhagenCompletedObesity | Appetite | Fecal Fat IncreasedDenmark
-
Sun Pharmaceutical Industries LimitedTerminatedActive Ankylosing Spondylitis or Non-Radiographic Axial SpondyloarthritisUnited States, Hungary, Poland, Spain
-
University Hospital Inselspital, BerneCompletedCoronary Artery DiseaseSwitzerland
-
Merck Sharp & Dohme LLCTerminated